CanAg CA19-9 EIA [CE]

TheCanag CA 19-9is intended for the quantitative determination of thecancerassociaciated antigen CA-19-9 in Serum TheCanAg CA19-9 EIAis a solid-phase, non-competitive immunoassay based upon the direct sandwich technique. Calibrators, controls and patient samples are incubated together with a biotinylated Anti-CA19-9 monoclonal antibody (MAb) C192 (derived from mice) in streptavidin coated microstrips. CA19-9 present in calibrators or samples is adsorbed to the streptavidin coated micro- strips b